New imaging agent targets hard-to-treat cancers in early trial
Diagnosis
Not yet recruiting
This early study tests a new radioactive antibody (NTH-2403) that attaches to a protein found on certain cancer cells and their supporting cells. The goal is to see if it can safely light up tumors on scans in people with advanced colorectal, head and neck, lung, or triple-negati…
Phase: PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated May 11, 2026 20:47 UTC